INCLUSION CRITERIA

• Males and females between 2 and 18 years of age
• Confirmed diagnosis of HIV-1 infection
• Viral load > 1500 RNA copies/mL
• Acceptable screening laboratory values indicative of adequate baseline organ function
• Signed informed consent prior to study participation from the patient or legal guardian
• Ability to take medications and comply with requirements of the protocol

EXCLUSION CRITERIA

• Female patients of childbearing potential who: * have a positive serum pregnancy test at screening * are breast feeding * are planning on becoming pregnant * are not willing to use two methods of contraception
• Active hepatitis B or C disease
• Life expectancy <12 months
• Patients who are unwilling to abstain from ingesting contraindicated medications and substances which may significantly affect plasma levels of the study medications
• Active substance abuse
• Use of investigational medications or vaccines within 28 days before study entry or during the trial
• Requirement for any therapy for malignancy or immunomodulatory drug
• Any active opportunistic infection within 28 days before study entry or other clinically significant findings that may compromise the outcome of the study
• Patients with malabsorption, severe chronic diarrhea or vomiting
• Evidence of symptoms of encephalopathy or developmental delay that would reduce compliance